-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Maintains Underweight on Bristol-Myers Squibb, Lowers Price Target to $40

Benzinga·10/30/2026 17:51:06
Listen to the news
Morgan Stanley analyst Terence Flynn maintains Bristol-Myers Squibb (NYSE:BMY) with a Underweight and lowers the price target from $41 to $40.